08:49 AM EDT, 04/09/2024 (MT Newswires) -- Alkermes ( ALKS ) said Tuesday that its phase 1b study of ALKS 2680, a once-daily potential treatment for narcolepsy, showed enhanced wakefulness in patients with narcolepsy type 2 and idiopathic hypersomnia.

ALKS 2680 showed "clinically meaningful and statistically significant improvements" in mean sleep latency compared with placebo across all doses tested in both patient groups, the company said, adding the investigational drug was also generally well-tolerated.

Alkermes ( ALKS ) said it plans to start a phase 2 study in narcolepsy type 2 patients in H2.

The company's shares were up nearly 7% in Tuesday premarket activity.

Price: 27.72, Change: +1.79, Percent Change: +6.9